Last reviewed · How we verify
GPRC5D CAR-T cell intravenous infusion
At a glance
| Generic name | GPRC5D CAR-T cell intravenous infusion |
|---|---|
| Sponsor | Qi deng |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening (EARLY_PHASE1)
- Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma (PHASE1)
- Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders (EARLY_PHASE1)
- Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment (NA)
- Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM (NA)
- To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma (EARLY_PHASE1)
- A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma (PHASE1)
- Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GPRC5D CAR-T cell intravenous infusion CI brief — competitive landscape report
- GPRC5D CAR-T cell intravenous infusion updates RSS · CI watch RSS
- Qi deng portfolio CI